The overarching goal of the Immunology Program is to define the basic mechanisms that control immunity in order to develop and optimize immunotherapies that generate a specific and durable anti-tumor immune response. To achieve this goal, we have strong research themes in place focused on the following Aims: 1) To elucidate the mechanisms that control immune tolerance, 2) To understand the development and maintenance of immunological memory, and 3) To develop and optimize cancer immunotherapies. The Immunology Program is led by Yoji Shimizu, PhD, and new co-leader, Jeffrey Miller, MD. Drs. Shimizu and Miller work collaboratively to accelerate Immunology Program research findings through the translational pipeline. Dr. Shimizu works with Immunology Program members to move high-impact and innovative basic research advances into cancer-relevant models and preclinical studies, and Dr. Miller bridges the basic science discoveries to resources within the Masonic Cancer Center in order to ultimately translate Immunology Program research findings into phase 1 clinical trials. The Program has 22 members, representing 9 departments and 3 schools or colleges (Medical School, College of Science and Engineering, and College of Veterinary Medicine). For the last budget year, these members were supported by $2.5 million in direct costs from the National Cancer Institute; funding from all peer-reviewed sources totaled $7.6 million in direct costs. Since 2013, Program members have published 354 papers (21% in journals with an impact factor >10), 24% of which resulted from intraprogrammatic collaborations, 23% from interprogrammatic collaborations, and 80% from external collaborations. Since 2013, 74 clinical trials in all clinical research categories have opened under this programmatic area and have accrued 203 patients. Access to Masonic Cancer Center Shared Resources, particularly Flow Cytometry and Translational Cell Therapy, is essential to the success of the Immunology Program. The Masonic Cancer Center has also enhanced Program activities through new faculty recruitments and funding of 4 pilot projects that resulted in 3 NCI-funded grants and a total ROI of $4.5M. The MCC supported and funded 21 monthly seminars that included 5 invited external speakers. Extensive intraprogrammatic and interprogrammatic interactions are enhanced by regular research-in-progress supergroup meetings, a faculty-only data club, a journal club, and an annual retreat sponsored by the Masonic Cancer Center. Program members also play a leadership role in training the next generation of cancer researchers. The Immunology Program research is aligned with the Masonic Cancer Center's strategic Scientific Priority for Growth (SPG1) to expand recent discoveries in immunotherapy and cellular therapeutics to include solid tumors. Furthermore, the Program's research addresses the elevated rates of myeloid leukemia and melanoma in Minnesota as well as developing novel therapies to reduce cancer morbidity and mortality for the major cancer burdens in MN: prostate, breast, lung.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Minnesota Twin Cities
United States
Zip Code
Lin, Lifeng; Chu, Haitao; Murad, Mohammad Hassan et al. (2018) Empirical Comparison of Publication Bias Tests in Meta-Analysis. J Gen Intern Med 33:1260-1267
Rashidi, Armin; Ebadi, Maryam; Said, Bassil et al. (2018) Absence of early HHV-6 reactivation after cord blood allograft predicts powerful graft-versus-tumor effect. Am J Hematol :
Bejanyan, Nelli; Brunstein, Claudio G; Cao, Qing et al. (2018) Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD. Blood Adv 2:909-922
Bachanova, Veronika; Sarhan, Dhifaf; DeFor, Todd E et al. (2018) Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells. Cancer Immunol Immunother 67:483-494
Hupp, Meghan; Williams, Sarah; Dunnette, Brian et al. (2018) Comparison of evaluation techniques, including digital image analysis, for MYC protein expression by immunohistochemical stain in aggressive B-cell lymphomas. Hum Pathol :
Rashidi, Armin; Shanley, Ryan; Holtan, Shernan G et al. (2018) Pretransplant Serum Citrulline Predicts Acute Graft-versus-Host Disease. Biol Blood Marrow Transplant 24:2190-2196
Ma, Bin; Zarth, Adam T; Carlson, Erik S et al. (2018) Methyl DNA Phosphate Adduct Formation in Rats Treated Chronically with 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone and Enantiomers of Its Metabolite 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol. Chem Res Toxicol 31:48-57
Hatsukami, Dorothy K; Luo, Xianghua; Jensen, Joni A et al. (2018) Effect of Immediate vs Gradual Reduction in Nicotine Content of Cigarettes on Biomarkers of Smoke Exposure: A Randomized Clinical Trial. JAMA 320:880-891
Lee, Hak Rae; Leslie, Faith; Azarin, Samira M (2018) A facile in vitro platform to study cancer cell dormancy under hypoxic microenvironments using CoCl2. J Biol Eng 12:12
Yang, Libang; Herrera, Jeremy; Gilbertsen, Adam et al. (2018) IL-8 mediates idiopathic pulmonary fibrosis mesenchymal progenitor cell fibrogenicity. Am J Physiol Lung Cell Mol Physiol 314:L127-L136

Showing the most recent 10 out of 1013 publications